Status:
UNKNOWN
Adipose Tissue Inflammation in HFpEF
Lead Sponsor:
Heart Center Leipzig - University Hospital
Conditions:
Heart Failure With Preserved Ejection Fraction
Obesity
Eligibility:
All Genders
18+ years
Brief Summary
To evaluate the role of adipose tissue inflammation in patients with heart failure with preserved ejection fraction (HFpEF). Patients undergoing coronary artery bypass grafting with HFpEF and without ...
Detailed Description
Heart Failure with preserved Ejection Fraction (HFpEF) is a growing public health concern with an increasing incidence, high morbidity and mortality and no proven therapy to date. Better characterizat...
Eligibility Criteria
Inclusion
- HFpEF: Left ventricular ejection fraction ≥ 50%, NT-pro-BNP ≥ 125ng/l, evidence of structural heart diseases (diastolic dysfunction, left ventricular-hypertrophy or left atrial-dilatation), BMI ≥ 30kg/m²
- Non-HF patients: No history of heart failure, Left ventricular ejection fraction \> 50% and NT-pro-BNP \<125ng/l
Exclusion
- Previous cardiac surgery / coronary intervention / myocardial infraction
- Acute coronary syndrome (Serum levels of troponin T \>50 pg/ml)
- Left ventricular ejection fraction \< 50%
- Indication for concomitant valvular surgery
- Planned beating heart coronary bypass surgery
- Hemodynamic instability
- Contraindication for magnetic resonance imaging
- Pregnancy
- Age \< 18 years
- No informed consent possible
Key Trial Info
Start Date :
November 1 2019
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
March 15 2022
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT04886713
Start Date
November 1 2019
End Date
March 15 2022
Last Update
May 14 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Heart Centre at University Leipzig
Leipzig, Saxony, Germany, 04289